drugset / Trial / NCT07258680
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Phase 3
Enrolling by invitation
114 enrolled
N.N. Petrov National Medical Research Center of Oncology
Non-randomizedParallel-groupOpen-labelTreatment
Summary
There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study. For the first time, the effectiveness and toxicity of various first-line PTCL therapy programs in patients with T-cell lymphoma will be analyzed in the conditions of a single medical center of the N.N.Petrov National Research Medical Center of Oncology and optimal therapeutic tactics will be determined, taking into account significant prognostic factors based on effectiveness and toxicity a specific chemotherapy regimen.
Timeline
- Start
- 2013-10
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | — |
| Comparator | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | — |
| Comparator | Prednisone | Other / unclassified | 100 mg | — |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | — |